With an average median survival of 14 months, glioblastoma multiforme (GBM), the most common and most aggressive primary brain tumor occurring in adults, represents an unmet medical need and new therapeutic options with a significant impact on patients survival are eagerly awaited. Our laboratory recently identified the enzyme CD73 as a new target for cancer […]
Read More